However, the final cost at our clinic may vary depending on several factors, such as the type of injection, the dosage, and any additional services required
Important Notes Practical considerations for consistent research preparation and recordkeeping
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
The classification criteria then include a history of chronic widespread pain and the presence of 11 or more out of 18 tender points (TPs)
Tesofensine for Weight Loss and Metabolic Support As providers look for options to support patients who fail to reach their goals on first-line therapies, Tesofensine peptide therapy has emerged as a compelling clinical tool
